Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8457734 | 0.85 | KIF11 (0.54) | KIF11CES2CES1PPARGPPARA | |
| SCHEMBL342180 | 0.84 | CYP1A2 (0.41) | KIF11CYP1A2KMT2A | |
| SCHEMBL856139 | 0.84 | CYP1A2 (0.41) | KIF11CYP1A2KMT2A | |
| SCHEMBL1143417 | 0.80 | KIF11 (0.49) | KIF11CES2CES1KCNH2 | |
| SCHEMBL1235122 | 0.76 | KMT2A (0.48) | KIF11CES1ALDH1A1CYP1A2GAA | |
| SCHEMBL10179183 | 0.75 | CA4 (0.50) | KIF11CES2CES1ALDH1A1KCNH2 | |
| SCHEMBL10173286 | 0.75 | CA4 (0.50) | KIF11CES2CES1ALDH1A1KCNH2 | |
| Anisole SCHEMBL9404918 | 0.75 | KIF11 (0.47) | KIF11CES2CES1PPARGPPARA | |
| SCHEMBL6039133 | 0.75 | KIF11 (0.46) | KIF11CES2CES1NPC1RAB9A | |
| SCHEMBL14937220 | 0.74 | KIF11 (0.46) | KIF11SMN1; SMN2KCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556161-B2 | Inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-31 | — | — | US | disclosed |
| US-20150353549-A1 | Inhibitors Of Histone Deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-10 | — | — | US | disclosed |
| US-9150560-B2 | Inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-06 | — | — | US | disclosed |
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-20140171439-A1 | Inhibitors Of Histone Deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2014-06-19 | — | — | US | disclosed |
| US-8697717-B2 | Inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-04-15 | — | — | US | disclosed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | disclosed |
| US-8557825-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20130245034-A1 | Inhibitors Of Histone Deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-09-19 | — | — | US | disclosed |
| US-8455498-B2 | Inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-06-04 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-20050222414-A1 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
| US-20050113373-A1 | medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-26 | — | — | US | disclosed |
| US-20050096468-A1 | E.g., N,N-dimethyl,((5-(hydroxyaminocarbonyl)pyrimidin-2-yl)(piperazin-1,4-ylene)sulfonamide; bioavailability; oral administration; metabolic stability; side effect reduction; psoriasis; anticarcinogenic -proliferative, -arthritic, -inflammatory agent; gene therapy; genetic transcription potentiation | ACADIA WOODS PARTNERS, LLC | 2005-05-05 | — | — | US | disclosed |
| EP-1485099-A1 | INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| EP-1485364-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| EP-1485365-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003075929-A1 | INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076421-A1 | AMINOCARBONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076422-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222414-A1 | N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control | RELA, NFE2, HDAC1 | KIF11 4041/4885CES2 3744/4885CES1 1860/4885 |
| US-20050113373-A1 | medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample | HDAC1, HDAC11, HDAC4 | KIF11 2188/4885CES2 3365/4885CES1 966/4885 |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | KIF11 3491/4885CES2 522/4885CES1 201/4885 |
| US-20130245034-A1 | Inhibitors Of Histone Deacetylase | HDAC1, HDAC3, HDAC11 | KIF11 2614/4885CES2 1008/4885CES1 448/4885 |
| US-20140171439-A1 | Inhibitors Of Histone Deacetylase | HDAC1, HDAC3, HDAC11 | KIF11 2614/4885CES2 1008/4885CES1 448/4885 |
| US-20150353549-A1 | Inhibitors Of Histone Deacetylase | HDAC1, HDAC3, HDAC11 | KIF11 2614/4885CES2 1008/4885CES1 448/4885 |
| US-20050096468-A1 | E.g., N,N-dimethyl,((5-(hydroxyaminocarbonyl)pyrimidin-2-yl)(piperazin-1,4-ylene)sulfonamide; bioavailability; oral administration; metabolic stability; side effect reduction; psoriasis; anticarcinogenic -proliferative, -arthritic, -inflammatory agent; gene therapy; genetic transcription potentiation | HDAC1, HDAC2, HDAC11 | KIF11 3619/4885CES2 3406/4885CES1 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.